Skip to contentN
Nika Pharmaceuticals, Inc
N
NIKANika Pharmaceuticals, Inc Q3 2025 · 10-Q
Revenue—
Net Income-$8.00K-$8.00KN/M vs Q3 2024 EPS Diluted$0.00$0.00— vs Q3 2024 Operating Income-$7,999N/M Operating Cash Flowderived-$9,329N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nika Pharmaceuticals, Inc · CIK 1145604 · Engraved from SEC EDGAR
ended Sep 30, 2025 · filed Nov 7, 2025 · 38 d after period end